EMERYVILLE, Calif.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research ...
Figure 1. Antibody-based clinical trials by modality (ClinicalTrials.gov and Thera-SAbDab, Feb. 2026). mAbs have declined from roughly 95% to about two-thirds of the pipeline as programs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results